Intravitreal therapy for the management of diabetic retinopathy: A concise review.

Atul Arora, Arvind K Morya, Parul C Gupta, Nitin K Menia, Prateek Nishant, Vishali Gupta
{"title":"Intravitreal therapy for the management of diabetic retinopathy: A concise review.","authors":"Atul Arora, Arvind K Morya, Parul C Gupta, Nitin K Menia, Prateek Nishant, Vishali Gupta","doi":"10.5493/wjem.v14.i4.99235","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic retinopathy (DR) is a serious microvascular complication of diabetes mellitus and may result in irreversible visual loss. Laser treatment has been the gold standard treatment for diabetic macular edema and proliferative diabetic retinopathy for many years. Of late, intravitreal therapy has emerged as a cornerstone in the management of DR. Among the diverse pharmacotherapeutic options, anti-vascular endothelial growth factor agents have demonstrated remarkable efficacy by attenuating neovascularization and reducing macular edema, thus preserving visual acuity in DR patients.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 4","pages":"99235"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551706/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of experimental medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5493/wjem.v14.i4.99235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetic retinopathy (DR) is a serious microvascular complication of diabetes mellitus and may result in irreversible visual loss. Laser treatment has been the gold standard treatment for diabetic macular edema and proliferative diabetic retinopathy for many years. Of late, intravitreal therapy has emerged as a cornerstone in the management of DR. Among the diverse pharmacotherapeutic options, anti-vascular endothelial growth factor agents have demonstrated remarkable efficacy by attenuating neovascularization and reducing macular edema, thus preserving visual acuity in DR patients.

玻璃体内治疗糖尿病视网膜病变:简要回顾。
糖尿病视网膜病变(DR)是糖尿病的严重微血管并发症,可导致不可逆的视力丧失。多年来,激光治疗一直是治疗糖尿病黄斑水肿和增生性糖尿病视网膜病变的金标准。近年来,玻璃体内治疗已成为DR治疗的基石。在多种药物治疗方案中,抗血管内皮生长因子药物已显示出显著的疗效,可减少新生血管和减少黄斑水肿,从而保持DR患者的视力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信